IBIO - iBio, Inc.
NYSE
->
Healthcare
->
Biotechnology
Bryan,
United States
Type: Equity
IBIO price evolution
IBIO
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.71 | $14.1 | $1.24 | |
| Inventory | ||||
| Total current assets | $15.67 | $36.14 | $19.7 | $27.09 |
| Long term investments | ||||
| Property, plant & equipment | $6.37 | $6.61 | $6.93 | $7.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $28.73 | $50.15 | $34.02 | $44.39 |
| Current liabilities | ||||
| Accounts payable | $0.36 | $1.23 | $1.86 | $2.01 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.84 | $21.43 | $21.55 | $22.28 |
| Long term debt | $0.88 | $1.06 | $0.36 | $1.5 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $7.41 | $25.29 | $24.82 | $27 |
| Shareholders' equity | ||||
| Retained earnings | -$313.85 | -$306.07 | -$302.9 | -$282.91 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $77.4 | |||
| Short term investments | ||||
| Net receivables | $0.2 | $6.1 | $5.53 | |
| Inventory | $3.9 | $0.03 | ||
| Total current assets | $26.3 | $45.07 | $104.6 | |
| Long term investments | ||||
| Property, plant & equipment | $7.6 | $41.76 | $8.63 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $42.37 | |||
| Total investments | ||||
| Total assets | $41.2 | $99.41 | $146.97 | |
| Current liabilities | ||||
| Accounts payable | $1.8 | $4.26 | $2.25 | |
| Deferred revenue | $0.42 | |||
| Short long term debt | ||||
| Total current liabilities | $21.6 | $30.44 | $6.64 | |
| Long term debt | $0.6 | $0.03 | $31.75 | |
| Total noncurrent liabilities | $31.75 | |||
| Total debt | ||||
| Total liabilities | $25.8 | $35.92 | $38.4 | |
| Shareholders' equity | ||||
| Retained earnings | -$288.9 | -$223.93 | -$173.63 | |
| Other shareholder equity | -$0.21 | -$0.08 | ||
| Total shareholder equity | ||||
| (in millions $) | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.17 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.11 | $3.58 | $3.63 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.12 | $0.16 | -$0.01 | |
| Net income | ||||
| Net income | -$3.99 | -$7.78 | -$3.17 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.23 | $2.38 | $2.37 | |
| Cost of revenue | ||||
| Gross Profit | $2.17 | $0.91 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $16.86 | $28.77 | $50.1 | $32.48 |
| Operating income | -$31.11 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.19 | $0.03 | -$1.23 | $2.45 |
| Net income | ||||
| Net income | -$24.91 | -$65.01 | -$50.3 | -$23.21 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.71 | $0.91 | $1.05 | $0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.16 | $24.49 | $11.5 | $6.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.16 | $6.85 | -$1.15 | -$3.52 |
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 30 Jul 2021 |
|---|---|---|---|---|
| Net income | -$23.21 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$30.06 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.91 | $7.01 | -$5.13 | -$26.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $24.49 | $2.3 | -$6.13 | $78.83 |
| Effect of exchange rate | $0.03 | -$0 | ||
| Change in cash and equivalents | $6.85 | -$21.1 | -$48.73 | $22.29 |
News
|
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?
Insider Monkey · via Yahoo Finance
17 Feb 2025
|
|
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed...
Benzinga · via AOL
5 Jan 2025
|
|
iBio Expands Pipeline with New Antibody Agreement
TipRanks · via Yahoo Finance
5 Jan 2025
|
|
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed...
Benzinga · via Yahoo Finance
30 Dec 2024
|
|
12 Best Biotech Penny Stocks to Invest In
Insider Monkey via Yahoo Finance
24 Mar 2024
|
|
Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
InvestorPlace via Yahoo Finance
30 Sep 2023
|
|
27 Best Cheap Stocks To Buy Now
GoBankingRates via AOL
13 Jan 2023
|
|
iBio Inc. stock falls Wednesday, underperforms market
Market Watch
7 Dec 2022
|
|
27 Best Cheap Stocks To Buy Now
GoBankingRates via AOL
15 Nov 2022
|
|
27 Best Cheap Stocks To Buy Now
GoBankingRates via AOL
21 Oct 2022
|
Fundamentals
| Market cap | $11.38M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.62M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.08 |
| Quick ratio | N/A |